NCT07284173

A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

A Phase 1, Open Label, Fixed Sequence Study to Investigate the Effect of Rabeprazole on the Pharmacokinetics of PF-08049820 in Healthy Chinese Adult Participants.

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves. The study will take in healthy adult participants aged 18 to 65 years who are not able to have children. Eligible participants must weigh more than 50 kilograms (110 pounds) and have a Body Mass Index (BMI) between 18.5 and 27.9. Each participant will receive two treatments: * One treatment with PF-08049820 alone * One treatment with PF-08049820 taken together with rabeprazole Both medicines will be taken by mouth. Participants will stay at the study clinic for a few days during each treatment period. During these stays, the study team will collect blood samples to see how the body absorbs and processes the medicine.

Conditions

• Healthy Adults

Interventions

Type	Name	Description
DRUG	PF-08049820	Oral tablets
DRUG	Rabeprazole	Oral tablets

Timeline

• Start date: 2025-11-03
• Primary completion: 2025-12-15
• Completion: 2025-12-15
• First posted: 2025-12-16
• Last updated: 2025-12-16

Locations

2 sites across 1 country: China